Deal Snapshot: The two firms will seek to co-develop and co-commercialize targeted small molecule cancer therapies that they identify at the preclinical stage.
Who: BridgeBio Pharma/Helsinn Group
What: Building on a previous partnership, BridgeBio and Helsinn will co-develop a first-in-class GPX4 inhibitor as a potential drug therapy...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing
Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
